Effect of Nanotechnology Structured Water Magnalife for the Prevention of Recurrent Urinary Tract Infections.

University of Sulaimani

Status: Completed

Conditions: Recurrent Urinary Tract Infection

Treatments: Dietary Supplement: Nanotechnology Structured water Magnalife; Dietary Supplement: Ordinary bottled drinking water; Drug: Trimethoprim

Study type: Interventional

Funder types: Other

Identifiers

NCT04306731

College of Medicine

Details and patient eligibility

About

This study investigates nanotechnology structured water magnalife in urology and to test its effects against lower urinary tract infections (UTI) in females.

Full description

This study represents the first time to use nanotechnology structured water magnalife in urology and to test its effects against lower urinary tract infections (UTI) in females. Urinary tract infection (UTI ) is the second most common bacterial infection, affecting women at a much higher frequency than men. There is a higher rate of recurrence of UTI, and a recurrent infection will follow 25-35% of initial UTI episodes within 3-6 months.

Intermittent or prolonged low dose antibiotic therapy has been used to treat and prevent recurrent UTI. Emerging of resistance to antimicrobial agents, enormous economic burden, and the side effects of antibiotics have led to the search for an alternative non-antibiotic prophylaxis of recurrent UTI. Nanotechnology structured water is a new type of drinking water that has been prepared using different types of energy fields and electromagnetic fields to produce this structured water, which has new and different characteristics from the ordinary water.

In the current study, the efficacy of nanotechnology structured water magnalife was compared with low-dose Trimethoprim and bottled drinking water for the prevention of recurrent UTI.

Enrollment: 437 patients

Sex: Female

Ages: 24 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ≥ 2 (two or more than two) UTI in the last 6 months
• ≥ 3 (three or more than three) UTI in the last 12 months

Exclusion criteria

• immunotherapy
• radiotherapy
• malignancy
• steroids
• chronic infections
• chemotherapy
• immunosuppressive drugs
• anatomical abnormality of the urinary tract
• surgical operation the urinary tract

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

437 participants in 3 patient groups, including a placebo group

Interventional (Group M)

Experimental group

Description:

The group of patients given nanotechnology structured water magnalife

Treatment:

Dietary Supplement: Nanotechnology Structured water Magnalife

Control (Group T)

Active Comparator group

Description:

The group of patients given Trimethoprim

Treatment:

Drug: Trimethoprim

Placebo (Group O)

Placebo Comparator group

Description:

The group of patients given ordinary bottled drinking water

Treatment:

Dietary Supplement: Ordinary bottled drinking water